Milan, Italy – March 1, 2016 - Newron Pharmaceuticals S.p.A. (“Newron”), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of
Zambon is announcing today the availability and reimbursement on the Italian market of Xadago® (safinamide) as an add-on to levodopa alone or in combination with other Parkinson’
Milan, Italy, February 29, 2016 - Newron Pharmaceuticals S.p.A. (“Newron”), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of
Spain is the third country in which Xadago® is available for the treatment of adult patients with idiopathic Parkinson’s disease (PD)
Milan – February 22, 2016 – Zambon S.p.A.,
Milan, Italy – January 12, 2016 – Zambon S.p.A., an international pharmaceutical company strongly committed to the central nervous system (CNS) therapeutic area, and its partner
Milan, Italy – December 23, 2016 – Newron Pharmaceuticals S.p.A. (“Newron”, SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with
Financing Supports Clinical Development of Sarizotan for Patients with Rett Syndrome, a Rare Neurodevelopmental Disease
Milan, Italy – November 20, 2015 – Newron Pharmaceuticals S
Milan, November 13, 2015 – Zambon S.p.A., an International Pharmaceutical Company with a strong commitment in central nervous system (CNS) diseases, and its partner Newron
Meiji Seika Pharma Co., Ltd. (Headquarter: Tokyo, Japan, President: Daikichiro Kobayashi, “Meiji”) announces that it has initiated Phase II/III confirmatory and Phase III long-
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
